SCHEMBL31054239

SCHEMBL31054239

Cc1c(F)cccc1NC(=O)Nc1cccc(Cl)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.64
KMT2A Q03164 9/20 0.64
MAPT P10636 6/20 0.64
LMNA P02545 5/20 0.64
HTT P42858 3/20 0.64
ALDH1A1 P00352 3/20 0.64
RAB9A P51151 6/20 0.62
NPC1 O15118 5/20 0.59
KDM4E B2RXH2 3/20 0.59
TRPV1 Q8NER1 2/20 0.58
POLB P06746 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.57
GAA P10253 1/20 0.56
ALOX15 P16050 1/20 0.56
HSD17B10 Q99714 1/20 0.56
GRIK1 P39086 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.55
TP53 P04637 1/20 0.53
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6227015 0.87 MEN1 (0.71) MEN1KMT2AMAPTLMNAHTT
SCHEMBL6436290 0.86 KMT2A (0.68) MEN1KMT2AMAPTLMNAHTT
SCHEMBL12218116 0.83 MEN1 (0.68) MEN1KMT2AMAPTLMNAHTT
SCHEMBL14433741 0.82 MEN1 (0.74) MEN1KMT2AMAPTLMNAHTT
SCHEMBL4301183 0.82 KMT2A (0.82) MEN1KMT2AMAPTLMNAHTT
SCHEMBL17079616 0.81 DDX3X (0.79) MEN1KMT2AMAPTLMNAHTT
SCHEMBL23831948 0.81 KMT2A (0.60) MEN1KMT2AMAPTLMNAHTT
SCHEMBL15651820 0.81 MEN1 (0.60) MEN1KMT2AMAPTLMNAHTT
SCHEMBL30105161 0.81 KMT2A (0.60) MEN1KMT2AMAPTLMNAHTT
SCHEMBL30002285 0.80 MEN1 (0.68) MEN1KMT2AMAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4228630-B1 NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME UNIV FREIBURG ALBERT LUDWIGS (DE) 2025-03-05 EP claimed
US-20240277658-A1 NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2024-08-22 US claimed
US-20240277658-A1 NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2024-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277658-A1 NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME NLRP3, PYCARD, NLRP1 MEN1 3864/4885KMT2A 4020/4885MAPT 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.